BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
13 avr. 2022 08h00 HE
|
BriaCell Therapeutics Corp.
U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer.Fast Track improves the speed and frequency...
BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022
12 avr. 2022 16h30 HE
|
BriaCell Therapeutics Corp.
Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy.Bria-OTS™ will be used to treat patients with advanced...
BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial
07 avr. 2022 08h30 HE
|
BriaCell Therapeutics Corp.
Bria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™ formulation based on HLA-type.BriaCell and National...
BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment
28 févr. 2022 08h00 HE
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board
23 févr. 2022 08h00 HE
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer
16 févr. 2022 08h00 HE
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update
10 févr. 2022 08h00 HE
|
BriaCell Therapeutics Corp.
BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022Corporate buyback program continues; 1,031,672 shares and 200,740 warrants repurchased since...
BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders
19 janv. 2022 16h57 HE
|
BriaCell Therapeutics Corp.
NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), is pleased to announce that...
BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq
29 déc. 2021 20h48 HE
|
BriaCell Therapeutics Corp.
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 29, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Announces Insiders’ Intention to Purchase up to 10% of Public Market Securities
16 déc. 2021 08h00 HE
|
BriaCell Therapeutics Corp.
Insiders intend to acquire up to approximately 10% of BriaCell’s basic common shares, or 1.59 million sharesCorporate buyback program will continue; 501,703 shares and 143,236 warrants repurchased...